• Lung Cancer Group Cologne
  • Contact
  • Privacy Policy
  • English
    • Deutsch (German)
Netzwerk Genomische Medizin Lungenkrebs
  • Home
  • Health insurance companies
  • General information
  • Privacy Policy
  • Cookie Policy
  • Diagnostics
  • Hybrid-capture
  • Driver mutations
  • Fast-track analysis for first-line treatment
  • Driver mutations in lung cancer
  • Network Genomic Medicine – Lung Cancer
  • New therapeutic approaches from genomic research
  • New immunotherapeutic therapeutic approaches
  • Molecular Diagnostics
  • Contact
  • Imprint
  • Second Opinion service
  • Service invoicing
    • For pathologists
  • Map
  • Clinical trials
    • General information
    • Lung Cancer Study Group
    • What is a clinical trial?
    • Participation in a trial
  • The Network
    • Aims
    • Funding
    • Network Genomic Medicine cancer information system (NGMcis)
    • Publications
    • Related links
    • Our team
  • Ärzte
  • Veranstaltungen
Select Page

Spatial Tumor Heterogeneity in Lung Cancer with Acquired Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Resistance: Targeting High-Level MET-Amplification and EGFR T790M Mutation Occurring at Different Sites in the Same Patient.

Scheffler M, Merkelbach-Bruse S, Bos M, Fassunke J, Gardizi M, Michels S, Groneck L, Schultheis AM, Malchers F, Leenders F, Kobe C, König K, Heukamp LC, Sos ML, Thomas RK, Büttner R, Wolf J

Journal: J Thorac Oncol
Published: June 10, 2015

  • © 2016-2018 Network Genomic Medicine (NGM)
  • Contact
  • Imprint
  • Privacy Policy

Designed by Elegant Themes | Powered by WordPress